works with clients to review existing coverage, for adequacy of current coverage, as well as any recommendations for additional coverage required for full protection.
We are pleased to make continued progress in our ABIP program and look forward to using the scientific guidance and assistance available through the EMEA's Orphan Medicinal Drug Program," said David Johnston, Nektar senior vice president of research and development.
ABIP is under development for the prevention of pulmonary fungal infections such as aspergillosis in high-risk immunosuppressed patients.
1) Using ABIP for patients at risk of developing the infection may potentially reduce the incidence of these infections, as well as associated high morbidity and mortality and significant treatment costs.
ABIP recently completed a multi-dose, dose escalation clinical study in preparation for pivotal trials to begin in 2007.